2020 | |
---|---|
Criterium: | Position: |
Overall Score: | 22 |
Total Project Funding per Partner: | 4 |
Total Number of Projects: | > 1000 |
2019 | |
Criterium: | Position: |
Overall Score: | 90 |
Total Project Funding per Partner: | 28 |
Total Number of Projects: | > 1000 |
Total number of projects: 3
As coordinator: 0
As participant: 0
Sole participant: 3
Coordinator / Participant Ratio: *
Total project funding [€]: | Projects [No]: | |||||
---|---|---|---|---|---|---|
Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
2022 | 35.000.000 | 0 | 35.000.000 | 1 | ||
2020 | 100.000.000 | 0 | 100.000.000 | 1 | ||
2019 | 36.000.000 | 0 | 36.000.000 | 1 |
Institution: | Projects [No]: |
---|
Total number of partners: 0
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 0
Frequent / Rare Partner Ratio: 0
Start date | Project | acronym | role | funding | partners |
---|---|---|---|---|---|
2022-08-01 | Clinical development of Rift Valley fever vaccines in endemic regions | RIFTVAX | coordinator | 35.000.000 | 1 |
2020-07-24 | PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19 | COVID-19 VACCINES | coordinator | 100.000.000 | 1 |
2019-01-01 | Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola | ECRC | coordinator | 36.000.000 | 1 |